2 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
or acceptable for use due to factors beyond our control.
Our third-party manufacturers may have unacceptable or inconsistent product quality success rates
DRS
MIRA
Mira Pharmaceuticals Inc
29 Jun 22
Draft registration statement
12:00am
affect the IND application, including those related to our non-clinical program, manufacturing and product quality for the investigational product … related to our non-clinical program, manufacturing and product quality for the investigational product, and related regulatory considerations.
We
- Prev
- 1
- Next